中国医疗-2025 年 GLP-1 消费者调研：可及性、可负担性与治疗周期改善-China Healthcare_ 2025 GLP-1 consumer survey_ improving access, affordability and treatment duration

ab 26 November 2025 Powered by YES UBS Evidence Lab Global Research China Healthcare 2025 GLP-1 consumer survey: improving access, affordability and treatment duration Wave 2 survey points to improving user fundamentals for GLP-1 drugs UBS Evidence Lab conducted the second wave of the China GLP-1 consumer survey (first wave in 2024). Our key takeaway is a generally improving user base for GLP-1 drugs in terms of access and affordability. In addition, we note users for both type 2 diabetes (T2DM) and weight ...